It is worth noting that a significant proportion of primary MM tumor cells express both BCMA and CD1d, rendering them susceptible to both BCAR and iNKT TCR-mediated targeting, although CD1d expression levels may fluctuate with respect to MM disease stages.21 The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.